Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Lila Sciences›
Products & Services
Catalyst

Lila Sciences› offers Catalyst

Product
Currently Offered

Catalyst gives partner science teams direct platform access to Lila Iris and AI Science Factories.

Loading
Overview

Catalyst is Lila's platform-access offering, giving partner teams direct use of Lila Iris and AI Science Factories alongside scientific experts to design, run, and interpret more experiments in less time. It turns existing research programs into faster, higher-confidence discovery engines.

Through a lab-as-a-service model, Catalyst converts fixed lab capacity and capital expenditure into an on-demand resource, expanding experimental throughput and reducing cycle times. Internal scientists can focus on strategy, design decisions, and downstream development rather than running and maintaining complex lab workflows.

Catalyst - Classification

Model
  • AI Platform

More from Lila Sciences

  • Creation logo

    Creation

Catalyst - Direct Competitors

  • Insilico Medicine

    Insilico Medicine logo

    Pharma.ai

    insilico.com

  • Recursion Pharmaceuticals

    Recursion Pharmaceuticals logo

    Recursion OS

    recursion.com

AttributeCatalystPharma.aiRecursion OS
ProviderLila Scienceslila.ai$550M raised · Series AInsilico Medicineinsilico.com$401.3M raised · Series DRecursion Pharmaceuticalsrecursion.com$665.4M raised · Public
Founded202320142013
Sells ToEnterpriseEnterpriseEnterprise
Pricing Model—Recurring, SoftwareRecurring, Software
OwnershipVenture-backed private companyVenture CapitalPublic, Venture Capital
Catalyst

Provider Lila Scienceslila.ai$550M raised · Series A

Founded 2023

Sells To Enterprise

Pricing Model —

Ownership Venture-backed private company

Pharma.ai

Provider Insilico Medicineinsilico.com$401.3M raised · Series D

Founded 2014

Sells To Enterprise

Pricing Model Recurring, Software

Ownership Venture Capital

Recursion OS

Provider Recursion Pharmaceuticalsrecursion.com$665.4M raised · Public

Founded 2013

Sells To Enterprise

Pricing Model Recurring, Software

Ownership Public, Venture Capital

Catalyst - Similar Products & Services

  • GEMS AI Platform logo

    GEMS AI Platform

  • Drug Design Engine logo

    Drug Design Engine